Evidence map›Paper›PMID 39296952›Full record

ArticleJournal of psoriasis and psoriatic arthritis2023

Factors Associated with Multi-Biologic Use in Psoriasis Patients at an Academic Medical Center and Review of Biologic Survival.

Edward Hadeler, Sugandh Kumar, Samuel Yeroushalmi, Julie Hong, Elizabeth Wallace, George Han, Megan Mosca, Erin Bartholomew, Mimi Chung, Marwa Hakimi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psoriasis and psoriatic arthritis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Edward HadelerDepartment of Dermatology, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-3005-6529
Sugandh KumarDepartment of Dermatology, University of California, San Francisco, CA, USA.
Samuel YeroushalmiDepartment of Dermatology, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-8327-3279
Julie HongDepartment of Dermatology, University of California, San Francisco, CA, USA.
Elizabeth WallaceDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
George HanDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Megan MoscaDepartment of Dermatology, University of California, San Francisco, CA, USA.
Erin BartholomewDepartment of Dermatology, University of California, San Francisco, CA, USA.
Mimi ChungDepartment of Dermatology, University of California, San Francisco, CA, USA.
Marwa HakimiDepartment of Dermatology, University of California, San Francisco, CA, USA.
Soumya ReddyNew York University Langone Health, New York, NY, USA.
Jose ScherNew York University Langone Health, New York, NY, USA.
Tina BhutaniDepartment of Dermatology, University of California, San Francisco, CA, USA.
George GondoNational Psoriasis Foundation, Portland, OR, USA.ORCID https://orcid.org/0000-0002-6468-0397
April ArmstrongDepartment of Dermatology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Stacie BellOpsis Health/Global Nutrition Project, Golden, CO, USA.ORCID https://orcid.org/0000-0002-9987-567X
Wilson LiaoDepartment of Dermatology, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-7883-6439

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite their impressive efficacy in phase 3 trials, biologic agents for psoriasis (PsO) may lose efficacy over time. The factors associated with loss of efficacy have yet to be fully elucidated. Objective: We aimed to identify factors associated with PsO patients using multiple biologics in comparison to patients who used 1 biologic. We also reviewed the literature comparing the survival of different biologic agents for PsO. Methods: We examined clinical data from 222 psoriasis patients at the University of California San Francisco, of whom 51 reported use of 3 or more biologics and of whom 171 reported use of only a single biologic agent at the time of enrollment into a research database from 2006-2020. Results: In univariate analysis, duration of PsO, initial presentation of PsO on the gluteal cleft, erythrodermic psoriasis, and acne were associated with using 3 or more biologics. In multivariate analysis, duration of PsO, erythrodermic psoriasis, and acne remained significant. Our review of biologic survival revealed differences according to biologic class. Conclusion: We identified novel factors associated with multi-biologic use in PsO. Further studies in this area are needed to achieve a precision medicine approach.

Indexed as

biologic failurebiologic persistencebiologic survivalmulti-biologic usepsoriasis

Identifiers

PMID39296952
PMCPMC11361481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.